Bipolar Disorder Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Nov 2023

Pages: 161

SKU: IRTNTR76803

Snapshot

Bipolar Disorder Therapeutics Market Forecast 2024-2028

The Bipolar Disorder Therapeutics Market size is estimated to grow by USD 787.02 million at a CAGR of 2.68% between 2023 and 2028. The prevalence of Bipolar Disorder is increasing, fueling demand for more effective treatment options. Factors like heightened awareness, advanced diagnostics, and reduced stigma contribute to this demand, leading to more individuals seeking diagnosis and treatment. These developments positively impact market growth and forecasting. A significant factor shaping the market is the growing prevalence of personalized treatment.

Advances in genetics and neuroscience drive a focus on customized care, utilizing genetic data and improved understanding of brain function to tailor treatments. Key Market Drivers include the rising prevalence of Bipolar Disorder and increased demand for efficient treatment alternatives. Similarly, Key Market Trends highlight the increased prevalence of personalized treatment due to advances in genetics and neuroscience.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

This report provides a detailed analysis of the market by Drug Class (Antipsychotics, Mood stabilizers, Antidepressants, and Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

By Drug Class

The antipsychotics segment is estimated to witness significant growth during the forecast period. This segment in the global market has emerged as a leading drug class and holds the dominant share in terms of revenue. In addition, bipolar disorder symptoms such as mood swings and mood swings treatment, delusions, and hallucinations are widely treated with this drug class. Furthermore, since this drug class works exceptionally well at regulating mood and reducing the intensity of manic or depressive episodes, antipsychotic drugs have gained significant traction in the global market.

Get a glance at the market contribution of various segments Download PDF Sample

The antipsychotics segment was the largest segment and was valued at USD 2.29 billion in 2018. Moreover, Seroquel, Olanzapine, and Aripiprazole are three significant examples of antipsychotic medications that are often recommended for bipolar disorder management. In addition, these drugs have been essential in treating bipolar disorders for a long time and are commonly included in complete treatment plans, often used in combination with mood stabilizers. Furthermore, the significance of antipsychotics in the field of bipolar disorder treatment is evident from current market trends, which reflect continuous R&D efforts aimed at generating more targeted and better-tolerated antipsychotic medications. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

By Distribution Channel

The hospital pharmacies segment holds a prominent position in the distribution channel segment in the global market. In addition, these are essential in making sure that patients with bipolar disorder can obtain and use their medications. Moreover, the flexibility to serve both inpatients and outpatients, professional advice from chemists, and quick access to a large selection of pharmaceuticals are among the benefits of using this channel. In addition, specialty pharmaceuticals such as mood stabilizers and antipsychotics that are needed to treat bipolar disorder are frequently kept in stock by hospital pharmacists. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

By Region

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are contributing to the market growth in North America include the region's well-established healthcare system, high incidence of bipolar disorder cases, and growing public awareness of mental health issues. In addition, Prominent pharmaceutical corporations such as Pfizer and Bristol-Myers Squibb, extensively engage in R&D to meet the unmet requirements of bipolar medications for patients, which is positively impacting the market. Moreover, the regional market is growing owing to the increasing demand in North America for antipsychotic drugs, antidepressants, and mood stabilizers. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape

The market is driven by government efforts, particularly in supporting medical institutions and scientific organizations focusing on women's mental health. Treatment options include mood stabilizers, anticonvulsants, antipsychotic drugs, antidepressants, and anti-anxiety drugs. Key medications such as Cariprazine, Aripiprazole, Olanzapine, and Lurasidone are administered orally or parenterally. Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants are common. Beta blockers and antipsychotic drugs are also used. Bipolar disorder treatments are crucial in the healthcare sector, often involving lithium and vasopressin hormone therapy for conditions like diabetes insipidus. Over-the-counter mood stabilizers and anticonvulsant drugs cater to Bipolar I disorder. Organizations like the National Institute of Mental Health play a vital role in addressing manic depression and related disorders.

Key Market Drivers

The increasing need for effective Mood Disorder Therapies and Mental Health Medications is a key driver shaping the market. This demand surge is propelled by factors such as heightened awareness, advanced diagnostics, and shifting social perceptions. With reduced stigma surrounding bipolar disorder, individuals are increasingly inclined to seek Psychiatric Interventions and treatments like Mood Stabilizers, Antipsychotic Drugs, and Antidepressants.

Additionally, options such as Psychotherapy, Cognitive Behavioral Therapy, and Electroconvulsive Therapy offer varied approaches to managing the condition. This evolving landscape also embraces diverse care settings, including Hospitalization and Outpatient Treatment, fostering comprehensive support for individuals battling bipolar disorder.

Significant Market Trends

A pivotal determinant influencing market growth is the escalating prevalence of personalized treatment, driven by strides in genetics and neuroscience. An expanding emphasis on tailored care pervades the global landscape, spurred by advancements in these fields. Furthermore, leveraging genetic data and enhanced comprehension of brain function empowers clinicians to customize therapies. For instance, genetic testing identifies distinctive markers associated with bipolar disorder, aiding in targeted drug recommendations.

Additionally, neuroimaging techniques unveil structural and functional brain aberrations, guiding treatment decisions and monitoring. These dynamics fuel market growth analysis, fostering a landscape conducive to enhanced Pharmacological Management and Therapeutic Approaches during the forecast period.

Major Market Challenges

The stigma surrounding mental health poses a significant hurdle to market growth. Despite increasing understanding and awareness, many individuals delay seeking therapy due to fears of social rejection or personal shame. Consequently, this stigma fosters non-compliance with prescribed treatments, delays in diagnosis, and limited access to care overall.

For instance, individuals with bipolar disorder may refrain from discussing their condition or seeking professional help out of concern for societal judgment, impeding their access to appropriate therapies. Thus, the prevalence of social stigma adversely affects market research and growth, impeding Market forecasting during the forecast period.

Key Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers products such as VRAYLAR as an adjunctive treatment for major depressive disorder.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.

Drug Class Outlook
- Antipsychotics
- Mood stabilizers
- Antidepressants
- Others
Distribution Channel Outlook
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Geography Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of the World (ROW)
  - Australia
  - Argentina
  - Brazil

Market Analyst Overview

The market offers a range of treatments for individuals experiencing mood stabilizer and anti-depressant drugs to manage their condition. These medications are administered orally or parenterally and include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants. Lithium, an essential element, is commonly used for mood stabilization. Despite the availability of over-the-counter options, government initiatives are crucial for addressing the disease burden. Treatment involves managing periods of depression and elevated mood, often requiring combination therapies to mitigate side effects. Pharmaceutical companies are continually developing new drugs, including long-acting injectable medications like aripiprazole, to improve outcomes for adults with bipolar I disorder.

The market addresses complex mental health conditions with various treatments. While diabetes insipidus can be a concern, over-the-counter (OTC) mood stabilizer medications offer some relief. Understanding the mechanism of action of drugs like monoamine oxidase inhibitors and benzodiazepines is crucial. The market is evolving with advancements in digital health technologies, including telemedicine and mobile apps, which enhance access to care. As healthcare expenditure rises, addressing mental health conditions becomes paramount. Diagnostic procedures are improving, ensuring accurate diagnoses and better treatment outcomes in this global market.

The Bipolar Disorder Drugs and Treatment Market addresses the specific needs of women, considering factors like route of administration - whether oral or parenteral. Various medications are utilized, including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressant drugs. Additionally, the use of lithium (Li) element is common in treatment protocols. However, the condition's complexity necessitates careful monitoring, as certain medications may pose risks such as diabetes insipidus.

Market Scope
Report Coverage	Details
Page number	161
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 2.68%
Market Growth 2024-2028	USD 787.02 million
Market structure	Fragmented
YoY growth 2023-2024(%)	1.96
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., Gedeon Richter Plc, GlaxoSmithKline Plc, H Lundbeck AS, Intra-Cellular Therapies Inc., Mallinckrodt Plc, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industry Ltd., The London Psychiatry Centre, Wockhardt Ltd., and Zydus Lifesciences Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and the Rest of the World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global bipolar disorder therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global bipolar disorder therapeutics market 2018 - 2022 ($ million)

4.2 Drug Class Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Drug Class Segment 2018 - 2022 ($ million)

4.3 Distribution Channel Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)

6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class

6.3 Antipsychotics - Market size and forecast 2023-2028
- Exhibit 34: Chart on Antipsychotics - Market size and forecast 2023-2028 ($ million)
- Exhibit 35: Data Table on Antipsychotics - Market size and forecast 2023-2028 ($ million)
- Exhibit 36: Chart on Antipsychotics - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Antipsychotics - Year-over-year growth 2023-2028 (%)

6.4 Mood stabilizers - Market size and forecast 2023-2028
- Exhibit 38: Chart on Mood stabilizers - Market size and forecast 2023-2028 ($ million)
- Exhibit 39: Data Table on Mood stabilizers - Market size and forecast 2023-2028 ($ million)
- Exhibit 40: Chart on Mood stabilizers - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Mood stabilizers - Year-over-year growth 2023-2028 (%)

6.5 Antidepressants - Market size and forecast 2023-2028
- Exhibit 42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million)
- Exhibit 43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million)
- Exhibit 44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%)

6.6 Others - Market size and forecast 2023-2028
- Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
- Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)

6.7 Market opportunity by Drug Class
- Exhibit 50: Market opportunity by Drug Class ($ million)
- Exhibit 51: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
- Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)

7.2 Comparison by Distribution Channel
- Exhibit 54: Chart on Comparison by Distribution Channel
- Exhibit 55: Data Table on Comparison by Distribution Channel

7.3 Hospital pharmacies - Market size and forecast 2023-2028
- Exhibit 56: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 57: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 58: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)

7.4 Retail pharmacies - Market size and forecast 2023-2028
- Exhibit 60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)

7.5 Online pharmacies - Market size and forecast 2023-2028
- Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
- Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
- Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 68: Market opportunity by Distribution Channel ($ million)
- Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 71: Chart on Market share by geography 2023-2028 (%)
- Exhibit 72: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 73: Chart on Geographic comparison
- Exhibit 74: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.9 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.10 Canada - Market size and forecast 2023-2028
- Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.11 UK - Market size and forecast 2023-2028
- Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 111: Market opportunity by geography ($ million)
- Exhibit 112: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 113: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 114: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 115: Overview on factors of disruption

11.4 Industry risks
- Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 117: Vendors covered

12.2 Market positioning of vendors
- Exhibit 118: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 119: AbbVie Inc. - Overview
- Exhibit 120: AbbVie Inc. - Product / Service
- Exhibit 121: AbbVie Inc. - Key news
- Exhibit 122: AbbVie Inc. - Key offerings

12.4 Astellas Pharma Inc.
- Exhibit 123: Astellas Pharma Inc. - Overview
- Exhibit 124: Astellas Pharma Inc. - Product / Service
- Exhibit 125: Astellas Pharma Inc. - Key news
- Exhibit 126: Astellas Pharma Inc. - Key offerings

12.5 AstraZeneca Plc
- Exhibit 127: AstraZeneca Plc - Overview
- Exhibit 128: AstraZeneca Plc - Product / Service
- Exhibit 129: AstraZeneca Plc - Key news
- Exhibit 130: AstraZeneca Plc - Key offerings

12.6 Bristol Myers Squibb Co.
- Exhibit 131: Bristol Myers Squibb Co. - Overview
- Exhibit 132: Bristol Myers Squibb Co. - Product / Service
- Exhibit 133: Bristol Myers Squibb Co. - Key news
- Exhibit 134: Bristol Myers Squibb Co. - Key offerings

12.7 Eli Lilly and Co.
- Exhibit 135: Eli Lilly and Co. - Overview
- Exhibit 136: Eli Lilly and Co. - Product / Service
- Exhibit 137: Eli Lilly and Co. - Key news
- Exhibit 138: Eli Lilly and Co. - Key offerings

12.8 Gedeon Richter Plc
- Exhibit 139: Gedeon Richter Plc - Overview
- Exhibit 140: Gedeon Richter Plc - Business segments
- Exhibit 141: Gedeon Richter Plc - Key news
- Exhibit 142: Gedeon Richter Plc - Key offerings
- Exhibit 143: Gedeon Richter Plc - Segment focus

12.9 GlaxoSmithKline Plc
- Exhibit 144: GlaxoSmithKline Plc - Overview
- Exhibit 145: GlaxoSmithKline Plc - Business segments
- Exhibit 146: GlaxoSmithKline Plc - Key news
- Exhibit 147: GlaxoSmithKline Plc - Key offerings
- Exhibit 148: GlaxoSmithKline Plc - Segment focus

12.10 H Lundbeck AS
- Exhibit 149: H Lundbeck AS - Overview
- Exhibit 150: H Lundbeck AS - Product / Service
- Exhibit 151: H Lundbeck AS - Key offerings

12.11 Mallinckrodt Plc
- Exhibit 152: Mallinckrodt Plc - Overview
- Exhibit 153: Mallinckrodt Plc - Business segments
- Exhibit 154: Mallinckrodt Plc - Key offerings
- Exhibit 155: Mallinckrodt Plc - Segment focus

12.12 Novartis AG
- Exhibit 156: Novartis AG - Overview
- Exhibit 157: Novartis AG - Business segments
- Exhibit 158: Novartis AG - Key offerings
- Exhibit 159: Novartis AG - Segment focus

12.13 Otsuka Holdings Co. Ltd.
- Exhibit 160: Otsuka Holdings Co. Ltd. - Overview
- Exhibit 161: Otsuka Holdings Co. Ltd. - Business segments
- Exhibit 162: Otsuka Holdings Co. Ltd. - Key offerings
- Exhibit 163: Otsuka Holdings Co. Ltd. - Segment focus

12.14 Pfizer Inc.
- Exhibit 164: Pfizer Inc. - Overview
- Exhibit 165: Pfizer Inc. - Product / Service
- Exhibit 166: Pfizer Inc. - Key news
- Exhibit 167: Pfizer Inc. - Key offerings

12.15 Sumitomo Pharma Co. Ltd.
- Exhibit 168: Sumitomo Pharma Co. Ltd. - Overview
- Exhibit 169: Sumitomo Pharma Co. Ltd. - Business segments
- Exhibit 170: Sumitomo Pharma Co. Ltd. - Key offerings
- Exhibit 171: Sumitomo Pharma Co. Ltd. - Segment focus

12.16 Sun Pharmaceutical Industries Ltd.
- Exhibit 172: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 173: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 174: Sun Pharmaceutical Industries Ltd. - Key offerings

12.17 The London Psychiatry Centre
- Exhibit 175: The London Psychiatry Centre - Overview
- Exhibit 176: The London Psychiatry Centre - Product / Service
- Exhibit 177: The London Psychiatry Centre - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 178: Inclusions checklist
- Exhibit 179: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 180: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 181: Research methodology
- Exhibit 182: Validation techniques employed for market sizing
- Exhibit 183: Information sources

13.5 List of abbreviations
- Exhibit 184: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

bipolar disorder therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis